Gouvernement fédéral : Questions médicales fréquentes
Nom anglais: Federal Government
Descriptor UI:D035082
Tree Number:N03.540.400.750
Termes MeSH sélectionnés :
Multicenter Studies as Topic
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Gouvernement fédéral : Questions médicales les plus fréquentes",
"headline": "Gouvernement fédéral : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Gouvernement fédéral : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-11",
"dateModified": "2025-03-06",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Gouvernement fédéral"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Agences gouvernementales",
"url": "https://questionsmedicales.fr/mesh/D006077",
"about": {
"@type": "MedicalCondition",
"name": "Agences gouvernementales",
"code": {
"@type": "MedicalCode",
"code": "D006077",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "N03.540.400"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Gouvernement fédéral",
"alternateName": "Federal Government",
"code": {
"@type": "MedicalCode",
"code": "D035082",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Sara Allin",
"url": "https://questionsmedicales.fr/author/Sara%20Allin",
"affiliation": {
"@type": "Organization",
"name": "North American Observatory on Health Systems and Policies, Toronto, ON Canada."
}
},
{
"@type": "Person",
"name": "Gul Mehar Javaid Bukhari",
"url": "https://questionsmedicales.fr/author/Gul%20Mehar%20Javaid%20Bukhari",
"affiliation": {
"@type": "Organization",
"name": "Federal Medical & Dental College, Islamabad, Pakistan."
}
},
{
"@type": "Person",
"name": "R U Khabriev",
"url": "https://questionsmedicales.fr/author/R%20U%20Khabriev",
"affiliation": {
"@type": "Organization",
"name": "N. A. Semashko National Research Institute of Public Health, 105064, Moscow, Russia."
}
},
{
"@type": "Person",
"name": "Lizhen Cui",
"url": "https://questionsmedicales.fr/author/Lizhen%20Cui",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Noël E Smith",
"url": "https://questionsmedicales.fr/author/No%C3%ABl%20E%20Smith",
"affiliation": {
"@type": "Organization",
"name": "American Academy of PAs, 2318 Mill Road, Suite 1300, Alexandria, VA 22314."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Clinical impact of pancreatic invasion in T1-stage distal bile duct cancer and prognostic factors associated with long-term survival: A multicenter study.",
"datePublished": "2024-07-25",
"url": "https://questionsmedicales.fr/article/39054662",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/jhbp.12042"
}
},
{
"@type": "ScholarlyArticle",
"name": "Imaging-based surrogate classification for risk stratification of hepatocellular carcinoma with microvascular invasion to adjuvant hepatic arterial infusion chemotherapy: a multicenter retrospective study.",
"datePublished": "2024-07-24",
"url": "https://questionsmedicales.fr/article/39051653",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/JS9.0000000000001903"
}
},
{
"@type": "ScholarlyArticle",
"name": "Psychosocial and clinical factors associated with depression among diabetic patients in Amhara region comprehensive specialized hospitals, Ethiopia, 2022; a multicenter prevalence study.",
"datePublished": "2024-06-19",
"url": "https://questionsmedicales.fr/article/38903662",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/hsr2.2195"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparison of accelerated and standard infliximab induction regimens in acute severe ulcerative colitis using propensity score analysis: a retrospective multicenter study in China.",
"datePublished": "2024-06-07",
"url": "https://questionsmedicales.fr/article/38855349",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1093/gastro/goae051"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparative effectiveness and tolerability of calcitonin gene-related peptide (CGRP) monoclonal antibodies and onabotulinumtoxinA in chronic migraine: A multicenter, real-world study in Taiwan.",
"datePublished": "2024-06-05",
"url": "https://questionsmedicales.fr/article/38837528",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/ene.16372"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Organisations et économie des soins de santé",
"item": "https://questionsmedicales.fr/mesh/D004472"
},
{
"@type": "ListItem",
"position": 3,
"name": "Organismes",
"item": "https://questionsmedicales.fr/mesh/D009938"
},
{
"@type": "ListItem",
"position": 4,
"name": "Agences gouvernementales",
"item": "https://questionsmedicales.fr/mesh/D006077"
},
{
"@type": "ListItem",
"position": 5,
"name": "Gouvernement fédéral",
"item": "https://questionsmedicales.fr/mesh/D035082"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Gouvernement fédéral - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Gouvernement fédéral",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-17",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Gouvernement fédéral",
"description": "Comment le gouvernement fédéral évalue-t-il les épidémies ?\nQuelles sont les méthodes de surveillance des maladies ?\nQuel rôle joue le gouvernement dans le diagnostic des maladies ?\nComment le gouvernement fédéral soutient-il le diagnostic précoce ?\nQuelles sont les normes de diagnostic établies par le gouvernement ?",
"url": "https://questionsmedicales.fr/mesh/D035082?mesh_terms=Multicenter+Studies+as+Topic&page=996#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Gouvernement fédéral",
"description": "Comment le gouvernement informe-t-il sur les symptômes des maladies ?\nQuels symptômes sont souvent associés aux épidémies ?\nComment le gouvernement traite-t-il les symptômes des maladies chroniques ?\nQuelles ressources le gouvernement offre pour les symptômes mentaux ?\nComment le gouvernement évalue-t-il les symptômes des nouvelles maladies ?",
"url": "https://questionsmedicales.fr/mesh/D035082?mesh_terms=Multicenter+Studies+as+Topic&page=996#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Gouvernement fédéral",
"description": "Quelles campagnes de prévention le gouvernement mène-t-il ?\nComment le gouvernement soutient-il la prévention des maladies chroniques ?\nQuelles sont les recommandations gouvernementales pour la prévention ?\nComment le gouvernement évalue-t-il l'efficacité des programmes de prévention ?\nQuelles ressources le gouvernement offre pour la prévention des maladies ?",
"url": "https://questionsmedicales.fr/mesh/D035082?mesh_terms=Multicenter+Studies+as+Topic&page=996#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Gouvernement fédéral",
"description": "Quel est le rôle du gouvernement dans le financement des traitements ?\nComment le gouvernement régule-t-il les traitements médicaux ?\nQuelles sont les initiatives gouvernementales pour les traitements innovants ?\nComment le gouvernement assure-t-il l'accès aux traitements ?\nQuelles sont les politiques de traitement des maladies infectieuses ?",
"url": "https://questionsmedicales.fr/mesh/D035082?mesh_terms=Multicenter+Studies+as+Topic&page=996#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Gouvernement fédéral",
"description": "Comment le gouvernement gère-t-il les complications des maladies ?\nQuelles sont les complications courantes des maladies infectieuses ?\nComment le gouvernement informe-t-il sur les complications possibles ?\nQuelles sont les politiques pour gérer les complications des maladies chroniques ?\nComment le gouvernement évalue-t-il les complications des traitements ?",
"url": "https://questionsmedicales.fr/mesh/D035082?mesh_terms=Multicenter+Studies+as+Topic&page=996#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Gouvernement fédéral",
"description": "Quels facteurs de risque le gouvernement identifie-t-il ?\nComment le gouvernement aborde-t-il les facteurs de risque ?\nQuelles données le gouvernement utilise pour évaluer les facteurs de risque ?\nComment le gouvernement sensibilise-t-il aux facteurs de risque ?\nQuelles initiatives le gouvernement prend-il pour réduire les facteurs de risque ?",
"url": "https://questionsmedicales.fr/mesh/D035082?mesh_terms=Multicenter+Studies+as+Topic&page=996#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment le gouvernement fédéral évalue-t-il les épidémies ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il utilise des données épidémiologiques et des rapports de santé publique pour évaluer les épidémies."
}
},
{
"@type": "Question",
"name": "Quelles sont les méthodes de surveillance des maladies ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les méthodes incluent les enquêtes, les systèmes de notification et les analyses de données."
}
},
{
"@type": "Question",
"name": "Quel rôle joue le gouvernement dans le diagnostic des maladies ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il établit des protocoles de diagnostic et finance des recherches pour améliorer les méthodes."
}
},
{
"@type": "Question",
"name": "Comment le gouvernement fédéral soutient-il le diagnostic précoce ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il finance des programmes de dépistage et sensibilise le public aux signes précoces."
}
},
{
"@type": "Question",
"name": "Quelles sont les normes de diagnostic établies par le gouvernement ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le gouvernement établit des lignes directrices basées sur des preuves pour le diagnostic."
}
},
{
"@type": "Question",
"name": "Comment le gouvernement informe-t-il sur les symptômes des maladies ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il publie des brochures, des sites web et des campagnes de sensibilisation sur les symptômes."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont souvent associés aux épidémies ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes varient, mais incluent souvent fièvre, toux, et fatigue selon la maladie."
}
},
{
"@type": "Question",
"name": "Comment le gouvernement traite-t-il les symptômes des maladies chroniques ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il finance des programmes de gestion des maladies chroniques et des traitements symptomatiques."
}
},
{
"@type": "Question",
"name": "Quelles ressources le gouvernement offre pour les symptômes mentaux ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il propose des lignes d'assistance, des programmes de santé mentale et des ressources en ligne."
}
},
{
"@type": "Question",
"name": "Comment le gouvernement évalue-t-il les symptômes des nouvelles maladies ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il collabore avec des experts pour identifier et évaluer les symptômes émergents."
}
},
{
"@type": "Question",
"name": "Quelles campagnes de prévention le gouvernement mène-t-il ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il organise des campagnes de vaccination, de dépistage et de sensibilisation à la santé."
}
},
{
"@type": "Question",
"name": "Comment le gouvernement soutient-il la prévention des maladies chroniques ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il finance des programmes de promotion de la santé et d'éducation sur les modes de vie sains."
}
},
{
"@type": "Question",
"name": "Quelles sont les recommandations gouvernementales pour la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le gouvernement publie des lignes directrices sur l'alimentation, l'exercice et le dépistage."
}
},
{
"@type": "Question",
"name": "Comment le gouvernement évalue-t-il l'efficacité des programmes de prévention ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il utilise des études d'impact et des analyses de données pour évaluer les programmes."
}
},
{
"@type": "Question",
"name": "Quelles ressources le gouvernement offre pour la prévention des maladies ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il propose des ressources en ligne, des brochures et des ateliers communautaires."
}
},
{
"@type": "Question",
"name": "Quel est le rôle du gouvernement dans le financement des traitements ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il finance la recherche et l'accès aux traitements par le biais de subventions et de programmes."
}
},
{
"@type": "Question",
"name": "Comment le gouvernement régule-t-il les traitements médicaux ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il établit des agences pour approuver et surveiller les traitements avant leur mise sur le marché."
}
},
{
"@type": "Question",
"name": "Quelles sont les initiatives gouvernementales pour les traitements innovants ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le gouvernement soutient des programmes de recherche et des essais cliniques pour les innovations."
}
},
{
"@type": "Question",
"name": "Comment le gouvernement assure-t-il l'accès aux traitements ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il met en place des programmes d'assurance santé et des politiques d'accès aux soins."
}
},
{
"@type": "Question",
"name": "Quelles sont les politiques de traitement des maladies infectieuses ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le gouvernement élabore des protocoles de traitement basés sur des recommandations scientifiques."
}
},
{
"@type": "Question",
"name": "Comment le gouvernement gère-t-il les complications des maladies ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il met en place des protocoles de traitement et des programmes de suivi pour les complications."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications courantes des maladies infectieuses ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent inclure des infections secondaires, des séquelles et des hospitalisations."
}
},
{
"@type": "Question",
"name": "Comment le gouvernement informe-t-il sur les complications possibles ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il publie des informations sur les risques et les complications associés aux maladies."
}
},
{
"@type": "Question",
"name": "Quelles sont les politiques pour gérer les complications des maladies chroniques ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le gouvernement finance des programmes de gestion des complications et de réhabilitation."
}
},
{
"@type": "Question",
"name": "Comment le gouvernement évalue-t-il les complications des traitements ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il surveille les effets secondaires et les complications par le biais de systèmes de rapport."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque le gouvernement identifie-t-il ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il identifie des facteurs comme le tabagisme, l'obésité et le manque d'exercice dans ses études."
}
},
{
"@type": "Question",
"name": "Comment le gouvernement aborde-t-il les facteurs de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il met en place des politiques de santé publique pour réduire les facteurs de risque identifiés."
}
},
{
"@type": "Question",
"name": "Quelles données le gouvernement utilise pour évaluer les facteurs de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il utilise des enquêtes de santé, des études épidémiologiques et des données démographiques."
}
},
{
"@type": "Question",
"name": "Comment le gouvernement sensibilise-t-il aux facteurs de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il organise des campagnes d'éducation et de sensibilisation sur les comportements à risque."
}
},
{
"@type": "Question",
"name": "Quelles initiatives le gouvernement prend-il pour réduire les facteurs de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il finance des programmes de prévention et des interventions communautaires ciblées."
}
}
]
}
]
}
The eighth edition of the AJCC staging system introduced a shift in the staging of distal bile duct cancer (DBC), emphasizing the depth of invasion over adjacent organ invasion. This study aimed to ev...
This multicenter retrospective analysis encompassed DBC patients who underwent pancreaticoduodenectomy between 2009 and 2019 in six Korean tertiary centers, specifically those with final pathology con...
This study involved 287 patients, comprising 190 without and 97 with pancreatic invasion. Pancreatic invasion did not significantly influence five-year OS and RFS rates (OS: without pancreatic invasio...
In pT1 DBC, pancreatic invasion demonstrates no substantial impact on long-term prognosis, in accordance with the depth-based paradigm of the eighth edition AJCC staging system. The prognostic factors...
Patients with microvascular invasion (MVI)-positive hepatocellular carcinoma (HCC) have shown promising results with adjuvant hepatic arterial infusion chemotherapy (HAIC) with FOLFOX after curative r...
Patients with MVI-positive HCC were identified from five academic centers and utilized for model development (n=470). Validation cohorts were pooled from a previously reported prospective clinical stu...
Arterial phase peritumoral enhancement, boundary of the tumor enhancement, tumor necrosis stratification, and boundary of the necrotic area were selected and incorporated into the nomogram for RFS. Th...
The utilization of this imaging-based model could help to better characterize MVI-positive HCC patients and facilitate the precise subtyping of patients who genuinely benefit from adjuvant HAIC treatm...
Depression commonly coexists with diabetes leads to complications and worsens the outcome. Even though the problem affects low- and middle-income countries including Ethiopia, only a few studies have ...
The main objective of this study was to assess psychosocial and clinical factors associated with depression among diabetic patients in Amhara region comprehensive specialized hospitals, Ethiopia, 2022...
A hospital-based cross-sectional study was conducted in randomly selected hospitals of Amhara region from January 7 to February 10, 2022. A total of 426 diabetic patients who were on outpatient follow...
Out of 426 interviewed diabetes patients 203 (47.7%) had depression. Moderate physical activity (AOR = 0.50, 95% CI (0.29, 0.86)). low medication adherence (AOR = 2.10, 95% CI (1.22, 3.62)), medium me...
The overall prevalence of depression among diabetic patients was higher than in other developing countries. Hence, special attention to preventing depression and maintaining mental illness among patie...
The optimal regimen of infliximab salvage in acute severe ulcerative colitis (ASUC) patients remains controversial. This study aimed to compare accelerated and standard infliximab induction in Chinese...
Data were retrospectively collected from steroid-refractory ASUC patients receiving infliximab as rescue therapy at seven tertiary centers across China. Outcomes including colectomy and clinical remis...
A total of 76 patients were analysed: 29 received standard and 47 received accelerated induction. The accelerated group had a higher 90-day colectomy rate (17.8% vs 0%,...
After adjusting for confounders, there were no significant differences in colectomy or clinical remission rates between accelerated and standard infliximab induction among ASUC patients. Early adminis...
To compare the real-world effectiveness and tolerability of calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) and onabotulinumtoxinA in chronic migraine (CM) patients....
This multicenter study involved retrospective analysis of prospectively collected data of CM patients treated with CGRP mAbs or onabotulinumtoxinA, including difficult-to-treat (DTT) patients (i.e., ≥...
The study included 316 (55 M/261F, mean age 44.4 ± 13.5 years) and 333 (61 M/272F, mean age 47.9 ± 13.4 years) CM patients treated with CGRP mAbs or onabotulinbumtoxinA, respectively. At 6 months, CGR...
In this multicenter, real-world study, CGRP mAbs were more effective than onabotulinumtoxinA in CM patients, even in DTT or MOH patients. All of these injectables were well tolerated. Further prospect...
Chimeric antigen receptor T-cell (CAR-T) therapy, despite being a potentially curative therapy in relapsed or refractory (RR) large B-cell lymphoma (LBCL), remains underutilized in older patients due ...
Isavuconazole (ISA) and voriconazole (VORI) are recommended as the first-line treatment for invasive aspergillosis (IA). Despite theoretical advantages of ISA, both triazole agents have not been compa...
We performed a post hoc analysis of 2 retrospective multicenter cohorts of solid organ transplant recipients with invasive fungal disease (the SOTIS [Solid Organ Transplantation and ISavuconazole] and...
Both groups were comparable in their demographics and major clinical and treatment-related variables. There were no differences in the rate of 12-wk clinical response between the ISA and VORI groups (...
Front-line treatment with ISA for posttransplant IA led to similar clinical outcomes than VORI, with better tolerability and higher treatment completion....
Detection of early neoplastic lesions is crucial for improving the survival rates of patients with gastric cancer. Optical enhancement mode 2 is a new image-enhanced endoscopic technique that offers b...
In this prospective multicenter randomized controlled trial, patients were randomly assigned to optical enhancement mode 2 or WLI groups. Detection of suspicious neoplastic lesions during the examinat...
A total of 1211 and 1219 individuals were included in the optical enhancement mode 2 and WLI groups, respectively. The detection rate of neoplastic lesions was significantly higher in the optical enha...
Optical enhancement mode 2 was more effective than WLI for detecting neoplastic lesions in the stomach, and can serve as a new method for screening early gastric cancer in clinical practice....
United States National Library of Medicine (https://www....
gov), ID: NCT040720521....
Previous studies suggested that the location of the primary tumor in non-small cell lung cancer (NSCLC) is associated with clinical features and prognosis, but results are conflicting. The purpose of ...
This study investigated the prognostic value of the geriatric nutritional risk index (GNRI) in patients undergoing curative gastrectomy for remnant gastric cancer (RGC)....
This multicenter retrospective study included 105 patients with RGC of ≥ 65 years of age who underwent curative gastrectomy at 10 institutions in Japan between January 2000 and December 2016. Postoper...
Receiver operating curve analyses indicated that the optimal cutoff value of the GNRI for OS was 95.4. Patients were categorized into high and low GNRI groups based on the optimal GNRI cutoff value. T...
The GNRI is a promising predictor of both short- and long-term outcomes in older patients with RGC....